U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Trump Administration Recalls Nearly 30 U.S. Ambassadors in Push for “America First” Agenda 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
U.S. Intercepts Venezuelan Oil Tanker in International Waters Amid Escalating Blockade Tensions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand 
Trump Administration Audits Somali-Origin Citizenship Cases Amid Fraud Allegations 
Federal Judge Upholds Trump Administration’s $100,000 H-1B Visa Fee 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Vanda Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its drug tradipitant, branded as Nereus, marking the first new FDA-approved treatment for motion-induced vomiting in more than 40 years. The company announced that it plans to launch the drug in the United States in the coming months, a move that could significantly change the treatment landscape for motion sickness.
Motion-induced vomiting, often referred to as motion sickness, occurs when the brain receives conflicting signals from the eyes, inner ear, and body sensors. This condition commonly affects people during travel activities such as boating, driving, or flying and has long relied on older treatment options with limited innovation.
The FDA’s approval of Nereus was supported by two late-stage clinical trials involving a total of 681 patients. Results from these studies showed that tradipitant significantly reduced episodes of vomiting compared to placebo. The drug works by blocking a specific brain receptor associated with nausea and vomiting, offering a targeted and modern approach to treatment.
According to H.C. Wainwright analyst Raghuram Selvaraju, peak annual sales of tradipitant for motion sickness alone could exceed $100 million in the U.S., highlighting its strong commercial potential. Currently available motion sickness treatments include Viatris’ scopolamine patch Transderm Scop, WellSpring Pharmaceutical’s Bonine, and Prestige Consumer Healthcare’s Dramamine, many of which have been on the market for decades.
Tradipitant’s regulatory journey faced challenges in the past. In December 2018, the FDA placed a partial clinical hold on the drug, requesting additional long-term toxicity studies in dogs after classifying motion sickness as a chronic condition. However, the agency reversed its stance, reclassifying motion sickness as an acute condition and lifting the clinical hold on December 4, eliminating the need for further studies.
Vanda licensed tradipitant from Eli Lilly in 2012 and continues to study the drug for multiple indications, including gastroparesis and nausea linked to certain diabetes medications. The company has not yet disclosed pricing details for Nereus.
